Pulmonary administration of chemically modified insulin
Details for Australian Patent Application No. 2002303869 (hide)
International Classifications
Event Publications
12 December 2002 Complete Application Filed
Priority application(s): 60/292,423 21.05.01 US
8 May 2003 Application Open to Public Inspection
Published as AU-B-2002303869
11 December 2003 Assignment before Grant
Inhale Therapeutic System Inc; Nektar Therapeutics AL, Corporation The application has been assigned to Nektar Therapeutics; Nektar Therapeutics AL, Corporation
11 December 2003 Change of Name(s) of Applicant(s), Section 104
Inhale Therapeutic Systems, Inc.; Shearwater Corporation The name of the applicant has been changed to Inhale Therapeutic Systems, Inc.; Nektar Therapeutics AL, Corporation
16 August 2007 Application Accepted
Published as AU-B-2002303869
13 December 2007 Standard Patent Sealed
16 July 2009 Assignment Registered
Nektar Therapeutics AL, Corporation; Nektar Therapeutics The patent has been assigned to Novartis AG
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2002303870-NUCLEOTIDE COMPOUNDS THAT BLOCK THE BITTER TASTE OF ORAL COMPOSITIONS
2002303868-Delivery of antihistamines through an inhalation route
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser